RT Journal Article
T1 Glycemic Dysregulations Are Associated With Worsening Cognitive Function in Older Participants at High Risk of Cardiovascular Disease: Two-Year Follow-up in the PREDIMED-Plus Study.
A1 Gómez-Martínez, Carlos
A1 Babio, Nancy
A1 Júlvez, Jordi
A1 Becerra-Tomás, Nerea
A1 Martínez-González, Miguel Á
A1 Corella, Dolores
A1 Castañer, Olga
A1 Romaguera, Dora
A1 Vioque, Jesús
A1 Alonso-Gómez, Ángel M
A1 Wärnberg, Julia
A1 Martínez, José A
A1 Serra-Majem, Luís
A1 Estruch, Ramón
A1 Tinahones, Francisco J
A1 Lapetra, José
A1 Pintó, Xavier
A1 Tur, Josep A
A1 López-Miranda, José
A1 Bueno-Cavanillas, Aurora
A1 Gaforio, José J
A1 Matía-Martín, Pilar
A1 Daimiel, Lidia
A1 Martín-Sánchez, Vicente
A1 Vidal, Josep
A1 Vázquez, Clotilde
A1 Ros, Emilio
A1 Dalsgaard, Søren
A1 Sayón-Orea, Carmen
A1 Sorlí, José V
A1 de la Torre, Rafael
A1 Abete, Itziar
A1 Tojal-Sierra, Lucas
A1 Barón-López, Francisco J
A1 Fernández-Brufal, Noelia
A1 Konieczna, Jadwiga
A1 García-Ríos, Antonio
A1 Sacanella, Emilio
A1 Bernal-López, M Rosa
A1 Santos-Lozano, José M
A1 Razquin, Cristina
A1 Alvarez-Sala, Andrea
A1 Goday, Albert
A1 Zulet, M Angeles
A1 Vaquero-Luna, Jessica
A1 Diez-Espino, Javier
A1 Cuenca-Royo, Aida
A1 Fernández-Aranda, Fernando
A1 Bulló, Mònica
A1 Salas-Salvadó, Jordi
K1 cognitive function
K1 diabetes duration
K1 glycated (glycosylated) hemoglobin
K1 insulin resistance
K1 prediabetes
K1 type 2 diabetes
AB Type 2 diabetes has been linked to greater cognitive decline, but other glycemic parameters such as prediabetes, diabetes control and treatment, and HOMA-IR and HbA1c diabetes-related biomarkers have shown inconsistent results. Furthermore, there is limited research assessing these relationships in short-term studies. Thus, we aimed to examine 2-year associations between baseline diabetes/glycemic status and changes in cognitive function in older participants at high risk of cardiovascular disease. We conducted a 2-year prospective cohort study (n=6,874) within the framework of the PREDIMED-Plus study. The participants (with overweight/obesity and metabolic syndrome; mean age 64.9 years; 48.5% women) completed a battery of 8 cognitive tests, and a global cognitive function Z-score (GCF) was estimated. At baseline, participants were categorized by diabetes status (no-diabetes, prediabetes, and  Prediabetes status was unrelated to cognitive decline. However, compared to participants without diabetes, those with ≥5-year diabetes duration had greater reductions in GCF (β=-0.11 (95%CI -0.16;-0.06)], as well as in processing speed and executive function measurements. Inverse associations were observed between baseline HOMA-IR and changes in GCF [β=-0.0094 (95%CI -0.0164;-0.0023)], but also between HbA1c levels and changes in GCF [β=-0.0085 (95%CI -0.0115, -0.0055)], the Mini-Mental State Examination, and other executive function tests. Poor diabetes control was inversely associated with phonologic fluency. The use of insulin treatment was inversely related to cognitive function as measured by the GCF [β=-0.31 (95%CI -0.44, -0.18)], and other cognitive tests. Insulin resistance, diabetes status, longer diabetes duration, poor glycemic control, and insulin treatment were associated with worsening cognitive function changes in the short term in a population at high cardiovascular risk. http://www.isrctn.com/ISRCTN89898870, identifier ISRCTN: 89898870.
SN 1664-2392
YR 2021
FD 2021-10-29
LK https://hdl.handle.net/10668/25680
UL https://hdl.handle.net/10668/25680
LA en
DS RISalud
RD Apr 6, 2025